Cellular Biomedicine Group Inc (NASDAQ:CBMG) has received an average broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating.
Zacks has also assigned Cellular Biomedicine Group an industry rank of 193 out of 265 based on the ratings given to related companies.
Several equities research analysts recently commented on CBMG shares. BidaskClub raised Cellular Biomedicine Group from a “hold” rating to a “buy” rating in a research report on Wednesday, January 10th. Maxim Group cut Cellular Biomedicine Group from a “buy” rating to a “hold” rating in a research report on Thursday, February 1st.
Hedge funds have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Cellular Biomedicine Group in the third quarter valued at about $107,000. Susquehanna International Group LLP bought a new position in Cellular Biomedicine Group in the second quarter valued at about $320,000. Finally, Goldman Sachs Group Inc. bought a new position in Cellular Biomedicine Group in the second quarter valued at about $540,000. 3.94% of the stock is currently owned by institutional investors.
Cellular Biomedicine Group (CBMG) traded down $1.05 during trading on Friday, hitting $16.75. The company had a trading volume of 46,306 shares, compared to its average volume of 60,808. Cellular Biomedicine Group has a 12 month low of $5.05 and a 12 month high of $22.75. The stock has a market capitalization of $254.92, a PE ratio of -9.74 and a beta of 3.54.
Cellular Biomedicine Group (NASDAQ:CBMG) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.43) EPS for the quarter. Cellular Biomedicine Group had a negative net margin of 7,579.14% and a negative return on equity of 42.56%. The business had revenue of $0.11 million for the quarter.
ILLEGAL ACTIVITY NOTICE: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/11/cellular-biomedicine-group-inc-cbmg-receives-consensus-recommendation-of-hold-from-brokerages.html.
Cellular Biomedicine Group Company Profile
Cellular Biomedicine Group, Inc (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.